Poniard Pharmaceuticals Report issue

For profit Phase 2 Phase 3
Founded: Seattle WA United States (1984)
Status: Acquired by Allozyne (2011) → now AstraZeneca (2014)

Organization Overview

First Clinical Trial
2002
NCT00045136
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Digestive System Neoplasms (Phase 1)

Gastrointestinal Neoplasms (Phase 1)

Lung Neoplasms (Phase 3)

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Plasmacytoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 8